RecruitingPHASE1, PHASE2NCT07185256

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Studying Best vitelliform macular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Opus Genetics, Inc
Intervention
OPGx-BEST1(genetic)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
20252030

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07185256 on ClinicalTrials.gov

Other trials for Best vitelliform macular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Best vitelliform macular dystrophy

← Back to all trials